SCHEDULE 13G: Summit Partners Entities Disclose Over 5% Stake in GeneDx Holdings Corp.

Multiple entities and individuals associated with Summit Partners have disclosed beneficial ownership of 5.19% of GeneDx Holdings Corp.'s Class A common stock.

Summary

• Summit Partners Public Asset Management, LLC and a group of related entities and individuals, including Philip Furse, Timothy Albright, Robert MacAulay, and Matthew Curtis, have reported beneficial ownership of 1,426,968 shares of GeneDx Holdings Corp. Class A common stock.
• This collective ownership represents 5.19% of the total outstanding Class A common stock.
• The ownership percentage is calculated based on 27,471,397 outstanding shares of Common Stock as of October 22, 2024, as reported in GeneDx Holdings Corp.'s Quarterly Report on Form 10-Q filed on October 29, 2024.
• Summit Partners Public Asset Management, LLC serves as the investment manager for shares and call options held by various Summit Partners funds (Summit Concentrated Growth L/S Master Fund, L.P., Summit Partners Technology L/S Master Fund, L.P., Summit Partners Sustainable Opportunities L/S Fund Limited, Summit Partners Sustainable Opportunities L/S QP Fund, L.P., and Summit Partners Sustainable Opportunities L/S Fund, L.P.) and a separately managed account.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It indicates institutional interest but provides no operational or financial performance data to sway sentiment positively or negatively.

Positives

• The disclosure of a significant institutional stake by Summit Partners, a prominent investment firm, may signal increased investor confidence in GeneDx Holdings Corp.'s prospects.
• The investment indicates a notable, albeit passive, interest from a group of sophisticated investors in the company.

Risks

• The filing includes a certification that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, with the specific exception for activities solely in connection with a nomination under Rule 14a-11. While generally indicating a passive investment, this exception suggests a potential for future engagement in director elections, which could be interpreted as a minor governance consideration.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Summit Partners, a prominent global investment firm, in GeneDx Holdings Corp. Such institutional investments are common in the biotechnology and healthcare sectors, reflecting investor interest in companies with potential for growth or innovation. While this filing does not provide specific industry analysis, it highlights the continued flow of capital into publicly traded companies within specialized fields.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Summit Partners may be viewed positively, potentially increasing investor confidence and liquidity, and identifies a major shareholder group.

Key Dates

Keywords

GeneDx Holdings Corp., Summit Partners, SEC filing, Schedule 13G, beneficial ownership, Class A common stock, institutional investment, equity stake, investment management